AV-101
VSG-CL-004
Phase 2 small_molecule active
Quick answer
AV-101 for Parkinson Disease is a Phase 2 program (small_molecule) at Vistagen Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Vistagen Therapeutics
- Indication
- Parkinson Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active